Upsher-Smith previews expansion of rare disease portfolio at 2024 AAN annual meeting

Upsher-Smith is showcasing its expanding portfolio of medications, including the Vigadrone (vigabatrin) product family and Torpenz (everolimus) Tablets slated for availability in mid-2024.

Since the successful launch of Vigadrone (vigabatrin) for Oral Solution, 500 mg to the specialty pharmacy channel in 2018, Upsher-Smith has broadened its offerings to include Vigadrone (vigabatrin) Tablets, 500 mg. Torpenz Tablets, a branded-generic everolimus tablet, will soon be available to prescribers and patients.

Central to Upsher-Smith’s commitment to rare disease communities is its Promise of Support Program, ensuring comprehensive assistance for patients, caregivers and healthcare providers throughout treatment. For more than five years, the program has offered resources for uninterrupted medication supply, prior authorization support, copay and patient assistance, patient education materials, collaboration with a leading specialty pharmacy partner and streamlined prescribing and enrollment procedures.

[Read more: Upsher-Smith extends fluoxetine product line]

Rich Fisher, president and chief operating officer of Upsher-Smith emphasized the company’s dedication to improving access and affordability to its products while prioritizing unparalleled service and support. “We understand the challenges faced by families battling rare diseases, and our team is steadfast in delivering solutions that ease some of the burden for patients and their families. We eagerly anticipate previewing our new everolimus option at this year’s American Academy of Neurology Annual Meeting and engaging attendees in discussions about the benefits of our Promise of Support Program.”

[Read more: Upsher-Smith extends generic Haldol line]